Skip to main content
SpringerLink
Log in

R-Flurbiprofen (E-7869), a chemopreventive and treatment of cancer

  • Published:
InflammoPharmacology Aims and scope Submit manuscript

Abstract

R-flurbiprofen, the non-COX inhibiting enantiomer of the non-steroidal antiinflammatory (NSAI) agent R-, S-flurbiprofen has proved to have a pharmacology independent of the S-enantiomer. In this presentation, we recount its anti-proliferative activity in the rat in addition to its anti-cancer activity without significant ulcerogenicity in the Min and TRAMP mouse models. In the Min mouse (a model of human FAP) R-flurbiprofen proved 'curative'. It had significant activity against both the primary lesion in the TRAMP mouse (a model of prostate cancer) and metastatic disease which was influenced by the amount of saturated fat in the diet. ___TAGSTART___BR___TAGEND___Surprisingly, we found R-flurbiprofen anti-inflammatory in the rat hind-paw edema assay. From our accumulating data, and the work of others, R-flurbiprofen has pro-apoptotic activity. We hypothesize that the mechanism of R-flurbiprofen's pro-apoptotic activity is inhibition of COX-2 m-RNA transcription and/or down-regulation of NFkB. We believe that R-flurbiprofen will delay or prevent progression of epithelial pre-malignant lesions to carcinoma (colon, prostate, lung and breast) without significant side effects. In addition, as hypothesized for other modifiers of cyclo-oxygenase activity, it may delay or prevent progression of Alzheimer's Disease. Phase I and IIa clinical studies with oral R-flurbiprofen (E-7869) have begun in normal volunteers and prostate cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCES

  • Lotsch, J., Geisslinger, G., Mohammadian, P., et al. (1995). Effects of flurbiprofen enantiomers on pain-related chemo-somatosensory evoked potentials in human subjects, Brit. J. Clin. Pharmacol. 40, 339–346.

    Google Scholar 

  • McCracken, J. D., Wechter, W. J., Liu, Y., et al. (1996). Antiproliferative effects of the enantiomers of flurbiprofen, J. Clin. Pharmacol. 36 (6), 540–545.

    PubMed  Google Scholar 

  • MDS Panlabs (1998). Report: Testing LOM-5 R-flurbiprofen in carrageenan-induced rat paw edema, July 9, 1998.

  • Rainsford, K. D. (1985). Newer anti-inflammatory drugs, in: Anti-Inflammatory and Antirheumatic Drugs, Vol. II (7), pp. 138–150. CRC Press, Florida.

    Google Scholar 

  • Riendeau, D., Charleson, S., Cromlish, W., et al. (1997). Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays, Canad. J. Physiol. Pharmacol. 75 (9), 1088–1095.

    Google Scholar 

  • Sausville, E. (1997). (Written communication): National Cancer Institute in vitro disease-oriented primary anti-tumor screen, Reports July 23–24, 1997.

  • Wechter, W. J. (1994). Drug chirality: On the mechanism of R-aryl propionic acid class NSAIDs. Epimerization in humans and the clinical implications for the use of racemates, J. Clin. Pharmacol 34 (11), 1036–1042.

    PubMed  Google Scholar 

  • Wechter, W. J., Bigornia, A. E., Murray, E. D., Jr., et al. (1993). Rac-Flurbiprofen is more ulcerogenic than its (S)-enantiomer, Chirality 5, 492–494.

    PubMed  Google Scholar 

  • Wechter, W. J., Kantoci, D., Murray, E. D., Jr., et al. (1997). R-Flurbiprofen chemoprevention and treament of intestinal adenomas in the APC Min/+ mouse model: Implications for prophylaxis and treatment of colon cancer, Cancer Research 57, 4316–4324.

    PubMed  Google Scholar 

  • Wechter, W. J., Leipold, D. D., Quiggle, D., et al. (1998a). Prostate cancer treatment by R-flurbiprofen in the Tramp mouse, Proc. Amer. Asso. Cancer Res. 40, Abstract #2613.

  • Wechter, W. J., McCracken, J. D., Kantoci, D., et al. (1998b). Mechanism of enhancement of intestinal ulcerogenicity of S-aryl propionic acids by their R-enantiomers in the rat, Digestive Dis. Sci. 43 (6), 1264–1274.

    Google Scholar 

  • Wechter, W.J., Murray, E.D., Jr., Gibson, K.M.,et al. (1999a). Disposition and pharmacokinetics of R-flurbiprofen in rat, mouse and monkey. Article in preparation for submission to J. Clin. Phar.

  • Wechter, W. J., Murray, E. D., Jr., Kantoci, D., et al. (1999b). Treatment studies of the APC Min/+ mouse with R-flurbiprofen and sulindac sulfone, Life Sciences 66–8, 745–753.

    Google Scholar 

Download references

Authors
  1. W. J. Wechter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. D. Leipold
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. D. Quiggle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. D. McCracken
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. D. Murray Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. E. Loughman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wechter, W.J., Leipold, D.D., Quiggle, D.D. et al. R-Flurbiprofen (E-7869), a chemopreventive and treatment of cancer. Inflammopharmacology 8, 189–206 (2000). https://doi.org/10.1163/15685600038224

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1163/15685600038224

Search

Navigation